Treatment of giardiasis in dogs: field clinical study to confirm the efficacy, safety, and acceptance of a metronidazole-based flavored oral suspension.
Sloane Jones, Philippe Briantais, Cristiano Von Simson, Eleonore De Meyrignac, Laure Poincelot, Delphine Rigaut
{"title":"Treatment of giardiasis in dogs: field clinical study to confirm the efficacy, safety, and acceptance of a metronidazole-based flavored oral suspension.","authors":"Sloane Jones, Philippe Briantais, Cristiano Von Simson, Eleonore De Meyrignac, Laure Poincelot, Delphine Rigaut","doi":"10.1186/s13071-025-06797-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Giardia duodenalis is a prevalent gastrointestinal parasite in dogs, causing diarrhea, vomiting, and weight loss. Metronidazole is a common treatment for this infection. This study aimed to evaluate the efficacy, safety, and acceptance of a flavored liquid metronidazole oral suspension in treating G. duodenalis in naturally infected dogs.</p><p><strong>Methods: </strong>A double-masked, vehicle-controlled, randomized, multi-center clinical field trial was conducted. Client-owned dogs with confirmed G. duodenalis infections were enrolled and randomized into AYRADIA-treated and control groups. The AYRADIA group received the metronidazole suspension at 0.2 ml/kg twice daily for 5 days, while the control group received a flavored vehicle suspension without metronidazole. Fecal samples were collected before and after treatment to assess G. duodenalis cyst counts. Clinical examinations and owner assessments were also performed to evaluate safety and treatment acceptance.</p><p><strong>Results: </strong>The study enrolled 180 dogs, with 129 included in the efficacy analysis. AYRADIA treatment resulted in a 99.92% reduction in G. duodenalis cyst counts, significantly higher than the reduction in the control group. Adverse events were similar between both groups (10%), mainly consisting of diarrhea and vomiting. The treatment was readily accepted by 99% of dogs.</p><p><strong>Conclusions: </strong>AYRADIA, administered at 0.2 ml/kg twice daily for 5 days, is highly effective in treating G. duodenalis infections in dogs. The treatment demonstrated a positive safety profile and excellent acceptance. This flavored oral suspension offers a valuable and convenient option for veterinarians managing giardiasis in dogs.</p>","PeriodicalId":19793,"journal":{"name":"Parasites & Vectors","volume":"18 1","pages":"169"},"PeriodicalIF":3.0000,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Parasites & Vectors","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13071-025-06797-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PARASITOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Giardia duodenalis is a prevalent gastrointestinal parasite in dogs, causing diarrhea, vomiting, and weight loss. Metronidazole is a common treatment for this infection. This study aimed to evaluate the efficacy, safety, and acceptance of a flavored liquid metronidazole oral suspension in treating G. duodenalis in naturally infected dogs.
Methods: A double-masked, vehicle-controlled, randomized, multi-center clinical field trial was conducted. Client-owned dogs with confirmed G. duodenalis infections were enrolled and randomized into AYRADIA-treated and control groups. The AYRADIA group received the metronidazole suspension at 0.2 ml/kg twice daily for 5 days, while the control group received a flavored vehicle suspension without metronidazole. Fecal samples were collected before and after treatment to assess G. duodenalis cyst counts. Clinical examinations and owner assessments were also performed to evaluate safety and treatment acceptance.
Results: The study enrolled 180 dogs, with 129 included in the efficacy analysis. AYRADIA treatment resulted in a 99.92% reduction in G. duodenalis cyst counts, significantly higher than the reduction in the control group. Adverse events were similar between both groups (10%), mainly consisting of diarrhea and vomiting. The treatment was readily accepted by 99% of dogs.
Conclusions: AYRADIA, administered at 0.2 ml/kg twice daily for 5 days, is highly effective in treating G. duodenalis infections in dogs. The treatment demonstrated a positive safety profile and excellent acceptance. This flavored oral suspension offers a valuable and convenient option for veterinarians managing giardiasis in dogs.
期刊介绍：
Parasites & Vectors is an open access, peer-reviewed online journal dealing with the biology of parasites, parasitic diseases, intermediate hosts, vectors and vector-borne pathogens. Manuscripts published in this journal will be available to all worldwide, with no barriers to access, immediately following acceptance. However, authors retain the copyright of their material and may use it, or distribute it, as they wish.
Manuscripts on all aspects of the basic and applied biology of parasites, intermediate hosts, vectors and vector-borne pathogens will be considered. In addition to the traditional and well-established areas of science in these fields, we also aim to provide a vehicle for publication of the rapidly developing resources and technology in parasite, intermediate host and vector genomics and their impacts on biological research. We are able to publish large datasets and extensive results, frequently associated with genomic and post-genomic technologies, which are not readily accommodated in traditional journals. Manuscripts addressing broader issues, for example economics, social sciences and global climate change in relation to parasites, vectors and disease control, are also welcomed.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
